Size: | Price | Quantity | |
---|---|---|---|
50 mg | $38.00 | ||
500 mg | $98.00 |
Omeprazole (73590-58-6) is a H+,K+-ATPase inhibitor (IC50 = 5.8 μM). Clinically useful antisecretory and antiulcer agent.1 Potent inhibitor of CYP2C19 (Ki=3.1 mM).2 Inhibits swelling-dependent chloride channels.3 Facilitates oral bioavailability of bioactive peptides such as oxytocin by raising stomach pH.4 Displays broad spectrum antiviral activity.5 Enhances efficacy of remdesivir (10-fold).6
References/Citations:
1) Satoh et al. (1989), Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats; J. Pharmacol. Exp. Ther., 248 806
2) Kuzin et al. (2018), Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine; Clin. Pharmacokinet, 57 729
3) Schmarda et al. (2000) The gastric H,K-ATPase blocker Iansoprazole is an inhibitor of chloride channels; Br. J. Pharmacol., 129 598
4) Maejima et al. (2020), Oral oxytocin delivery with proton pump inhibitor pretreatment decreases food intake; Peptides, 128 170312
5) Wantanabe et al. (2020), Selective Targeting of Virus Replication by Proton Pump Inhibitors; Sci. Rep., 10 4003
6) Bojkova et al. (2020), SARS-CoV2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles; bioRxiv, epub ahead of print DOI: 10.1101/2020.04.03.024257
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Omeprazole (73590-58-6) is a H+,K+-ATPase inhibitor (IC50 = 5.8 μM). Clinically useful antisecretory and antiulcer agent.1 Potent inhibitor of CYP2C19 (Ki=3.1 mM).2 Inhibits swelling-dependent chloride channels.3 Facilitates oral bioavailability of bioactive peptides such as oxytocin by raising stomach pH.4 Displays broad spectrum antiviral activity.5 Enhances efficacy of remdesivir (10-fold).6
References/Citations:
1) Satoh et al. (1989), Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats; J. Pharmacol. Exp. Ther., 248 806
2) Kuzin et al. (2018), Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine; Clin. Pharmacokinet, 57 729
3) Schmarda et al. (2000) The gastric H,K-ATPase blocker Iansoprazole is an inhibitor of chloride channels; Br. J. Pharmacol., 129 598
4) Maejima et al. (2020), Oral oxytocin delivery with proton pump inhibitor pretreatment decreases food intake; Peptides, 128 170312
5) Wantanabe et al. (2020), Selective Targeting of Virus Replication by Proton Pump Inhibitors; Sci. Rep., 10 4003
6) Bojkova et al. (2020), SARS-CoV2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles; bioRxiv, epub ahead of print DOI: 10.1101/2020.04.03.024257
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.